中国1992-2011年β-内酰胺类抗生素专利分析  

Analysis of β-lactam antibiotic patents issued in China in 1992-2011

作　　者：谢华[1] 任天舒[2] 郑岩[1] 胡萧[1] 马菲菲[1] 陈萍[1] 

机构地区：[1]沈阳军区总医院呼吸科,辽宁沈阳110840 [2]沈阳军区总医院药剂科,辽宁沈阳110840

出　　处：《中国药物应用与监测》2013年第1期48-51,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的:调研中国20年内β-内酰胺类抗生素专利情况,为新抗生素的研发提供思路。方法:检索中华人民共和国国家知识产权局网站(http://www.sipo.gov.cn)1992年1月–2011年12月的β-内酰胺类抗生素专利,对其进行统计分析。结果:共检索出1992–2011年1231项β-内酰胺类抗生素专利,专利数量逐年增加,2004年前专利数量较少,2005年后增多,2010年最多达262项;专利涉及18个国家,中国占82%;化学合成药品占77.8%;近年抗生素组合制剂专利增多,两个成分组合的有262项,占21.3%;头孢菌素类的种类和数量最多,有43类731项专利,专利数量前10位的依次是头孢呋辛、头孢克肟、头孢地尼、头孢哌酮、头孢噻呋、头孢吡罗、头孢吡肟、头孢替安、头孢孟多、头孢丙烯;青霉素类有15类246项专利,专利数量前5位的是羟氨苄青霉素、青霉素类、哌拉西林、美洛西林、萘夫西林;碳青霉烯类有8类87项,专利数量前2位的是亚胺培南和美罗培南。结论:我国β-内酰胺类抗生素的开发需要进行合理布局和必要的产品结构调整。Objective： To investigate β-lactam antibiotic patents issued in China in past 20 years to provide reference for development of new antibiotics. Methods： All data were obtained from the website of State Intellectual Property Office of the People＇s Republic of China from January 1992 to December 2011 and analyzed statistically. Results： A total of 1231 β-lactam antibiotic patents were granted in China during this period. The number of patents was less before 2004 and increased in 2005. There were 262 patents in 2010. Patents covered 18 countries, among which 82% was in China and the percentage of chemical synthesis products was 77.8%. There was an increase of patent numbers of antibiotic combinations in recent years, among which there were 262 species （21.3%） of two compositions combination. The species and numbers of cephalosporins were larger than other prducts, up to 43 kinds 731 patents. The top 10 patents in terms of the numbers were cefuroxime, cefixime, cefdinir, cefoperazone, ceftiofur, cefpirome, cefepime, cefotiam, cefamandole, cefprozil. There were totally 15 kinds 246 patents for penicillin. The top 5 patents in terms of the numbers were amoxycillin, penicillins, piperacillin, mezlocillin, nafcillin. There were totally 8 kinds 87 patents for the carbapenems. Conclusion： The development of β-lactam antibiotics in our country need rational distribution and adjustment of product structure.

关 键 词：Β-内酰胺类抗生素 头孢菌素类 专利 

分 类 号：R978.11[医药卫生—药品]